Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


New therapies under development promise improved relief for Non-Hodgkin’s Lymphoma cancer patients


Technical Insights’ Genetic Technology Alert

Biotech companies and researchers across the world are focusing on the development of new therapies for the treatment of Non-Hodgkin’s Lymphoma (NHL) cancer, a lethal and malignant disease that is spreading at an alarming rate.

"About 300,000 people in the United States are affected by NHL and it causes about 23,000 deaths each year in the U.S. alone," says Technical Insights Analyst Al Hester. "This has created a greater need for advanced NHL therapies."

Rituxan (rituximab), from the California-based IDEC Pharmaceuticals, was the first monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of a particular form of NHL. It has found widespread market acceptance and its sales surpassed the $1 billion per year mark.

The efficaciousness of the drug challenges developers of new therapies to discover treatment with some distinct advantages to differentiate their products and provide better relief for patients.

"The need for improved lymphoma treatments has by no means disappeared and a large market awaits developers of successful new products," says Hester.

Sensing the potential, many biotech firms have joined the global race for developing new NHL therapies despite being confronted by high production costs.

"Most of the new lymphoma therapies under development are monoclonal antibodies," says Hester. "These antibodies are high-priced proteins and, therefore, they are expensive to manufacture and also inconvenient to administer to the patients."

However, they can be generated to target specific therapeutic molecules. Biotech firms, betting on monoclonals for developing advanced lymphoma therapeutics, are targeting CD20 antigen that may be found on normal, as well as abnormal B cells. In addition, other antigens such as CD4, CD22, and CD30 are being targeted.

Some biotech firms are also trying gene therapy and vaccines to treat patients. These treatment methods could be advantageous as they avoid some of the side effects often associated with monoclonal antibodies, as well as the difficulties in gaining FDA approval.

The studies conducted by Genetic Technology Alert has revealed that the therapies market is capable of generating revenues worth more than $5 billion per year, as there is a steady increase in patient base.

New analysis by Technical Insights, a business unit of Frost & Sullivan (, featured in the Genetic Technology Alert, presents a critical insight of various therapies that are under research and different phases of clinical trials. The research also discusses the different approaches to treatment and highlights the prime qualities of these potential drugs. This is likely to provide a bird’s eye view of the emerging market opportunities.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and reports.

This analysis is part of the Genetic Technology Alert, which includes market insights on new developments in genetic technologies for the industry. Copies of the alert and interviews are available to the press.

Frost & Sullivan, an international growth consultancy, has been supporting clients’ expansion for more than four decades. Our market expertise covers a broad spectrum of industries, while our portfolio of advisory competencies include custom strategic consulting, market intelligence and management training. Our mission is to forge partnerships with our clients’ management teams to deliver market insights and to create value and drive growth through innovative approaches. Frost & Sullivan’s network of consultants, industry experts, corporate trainers and support staff, spans the globe with offices in every major country.

Julia Paulson | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>